User:Tkadm30/Notebook/Endocannabinoids/Synopsis: Difference between revisions
From OpenWetWare
| Line 2: | Line 2: | ||
* Stimulation of endocannabinoid transport with polyunsaturated (22:6n-3) fatty acids (DHA, EPA) to target [https://en.wikipedia.org/wiki/Major_depressive_disorder major depressive disorders] (MDD) , epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), posttraumatic stress disorder (PTSD), Parkinson's disease (PD), and Alzheimer's disease (AD). | * Stimulation of endocannabinoid transport with polyunsaturated (22:6n-3) fatty acids (DHA, EPA) to target [https://en.wikipedia.org/wiki/Major_depressive_disorder major depressive disorders] (MDD) , epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), posttraumatic stress disorder (PTSD), Parkinson's disease (PD), and Alzheimer's disease (AD). | ||
* Distribution of endocannabinoid-dependent activity (LTP, synaptogenesis) in the hippocampus promoting brain-derived neurotrophic factor (BDNF) expression, a biological marker for learning-dependent synapse formation. [https://www.ncbi.nlm.nih.gov/pubmed/21035522 PMID] [https://www.ncbi.nlm.nih.gov/pubmed/24360280 PMID] | * Distribution of endocannabinoid-dependent activity (LTP, synaptogenesis, CREB) in the hippocampus promoting brain-derived neurotrophic factor (BDNF) expression, a biological marker for learning-dependent synapse formation. [https://www.ncbi.nlm.nih.gov/pubmed/21035522 PMID] [https://www.ncbi.nlm.nih.gov/pubmed/24360280 PMID] | ||
* Intracellular CB1 signaling mediate on-demand neuroprotection on excitatory (glutamatergic) synapses | * Intracellular CB1 signaling mediate on-demand neuroprotection on excitatory (glutamatergic) synapses and in particular astrocytes. [https://www.ncbi.nlm.nih.gov/pubmed/21376829 PMID] [https://www.ncbi.nlm.nih.gov/pubmed/14526074 PMID] | ||
** DHA supplementation improves mitochondrial function and neuronal survival. [https://www.ncbi.nlm.nih.gov/pubmed/22248591 PMID] | ** DHA supplementation improves mitochondrial function and neuronal survival. [https://www.ncbi.nlm.nih.gov/pubmed/22248591 PMID] | ||
* Identification of a functional GPR40-GPR55 receptor heteromer with potent anti-inflammatory, antiglutamatergic and neuroprotective properties. | * Identification of a functional GPR40-GPR55 receptor heteromer with potent anti-inflammatory, antiglutamatergic and neuroprotective properties. | ||
Revision as of 05:05, 5 February 2016
Synopsis
- Stimulation of endocannabinoid transport with polyunsaturated (22:6n-3) fatty acids (DHA, EPA) to target major depressive disorders (MDD) , epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), posttraumatic stress disorder (PTSD), Parkinson's disease (PD), and Alzheimer's disease (AD).
- Distribution of endocannabinoid-dependent activity (LTP, synaptogenesis, CREB) in the hippocampus promoting brain-derived neurotrophic factor (BDNF) expression, a biological marker for learning-dependent synapse formation. PMID PMID
- Intracellular CB1 signaling mediate on-demand neuroprotection on excitatory (glutamatergic) synapses and in particular astrocytes. PMID PMID
- DHA supplementation improves mitochondrial function and neuronal survival. PMID
- Identification of a functional GPR40-GPR55 receptor heteromer with potent anti-inflammatory, antiglutamatergic and neuroprotective properties.
- Anti-proliferative effects of DHEA on prostate cancer cell lines. PMC
- A synaptogenic endocannabinoid promoting synaptogenesis.
- Antioxidant (cytoprotective) properties of GPR40-GPR55 heteromer.
- Effects of the endothelial CB2 receptor persistent activation on monocyte subpopulations/microglial activation PMID
- Caffeine is a adenosine antagonist which mediate CB1 receptor activation in the hippocampus PMID PMID
